– No dose-limiting toxicities or safety concerns observed in first cohort of treated patients
– Feasibility of streamlined, faster CAR therapy manufacturing process confirmed
– Dosing initiated in second cohort of patients
Gaithersburg, Maryland – May 8, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has initiated dosing for the second cohort of patients in its US Phase I clinical trial with MCY-M11, the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform. MCY-M11 is a mesothelin-targeting chimeric antigen receptor (CAR) therapy being tested in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.
The dose escalation trial is evaluating the safety and tolerability of MCY-M11 in approximately 15 patients across a series of cohorts.
“Successfully completing patient dosing in our first cohort and initiating dosing in a second higher-dose cohort are important milestones for MaxCyte, representing tangible progress for our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform,” said Claudio Dansky Ullmann, MD, Chief Medical Officer. “We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumors where the majority of patients still have very limited treatment options.”
Click here to read more.